

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司
Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in Cayman Islands with limited liability)
(Stock Code: 2005)

FURTHER DELAY IN DESPATCH OF CIRCULAR

As additional time is required to finalise the pro forma financial information regarding the assets and liabilities and the indebtedness statement of the enlarged Group to be included in the Circular, the Company has applied to the Stock Exchange for a further extension of the despatch date of the Circular from 22 May 2007 to a date falling on or before 11 June 2007.

Reference is made to the announcement (the “**Announcement**”) of the Company dated 30 March 2007 regarding a major and connected transaction and the announcement (the “**Delay Announcement**”) of the Company dated 20 April 2007 in relation to the delay in despatch of the Circular (as defined below). Terms used herein have the same respective meanings as those defined in the Announcement and the Delay Announcement unless the context requires otherwise.

FURTHER DELAY IN DESPATCH OF CIRCULAR

Pursuant to Rule 14.38 and Rule 14A.49 of the Listing Rules, the Company is required to despatch the circular (the “**Circular**”) containing, among other things, further details of the Acquisition to the Shareholders within 21 days after the publication of the Announcement, which shall have been on or before 23 April 2007. As announced in the Delay Announcement, the Company applied for a waiver from strict compliance with Rule 14.38 and Rule 14A.49 of the Listing Rules pursuant to which the despatch date of the Circular was extended from 23 April 2007 to a date falling on or before 22 May 2007.

In spite of the progress regarding the accountants' report of New Orient, additional time is required to finalise the pro forma financial information regarding the assets and liabilities and the indebtedness statement of the enlarged Group to be included in the Circular, and accordingly, the Directors anticipate additional time is required to prepare the Circular. The Company has applied to the Stock Exchange for the consent to further extend the despatch date of the Circular from 22 May 2007 to a date falling on or before 11 June 2007.

By order of the Board
Lijun International Pharmaceutical (Holding) Co., Ltd.
Wu Qin
Chairman

Hong Kong, 22 May 2007

As at the date of this announcement, the Board comprises Wu Qin, Wu Zhihong, Huang Chao, Xie Yunfeng, Sun Xinglai, and Wang Xian Jun as executive Directors, Liu Zhiyong as non-executive Director and Qu Jiguang, Leung Chong Shun and Chow Kwok Wai as independent non-executive Directors.